Our Team

Glenn Meyer, Phd

CMC, Product Development

A picture of Dr. Glenn Meyer, member of the Peptinovo team

Dr. Glenn Meyer has over 30 years of professional experience and, in 2012, founded Live Oak Pharmaceuticals Inc to provide pharmaceutical development, product profile and product development across all dosage forms, routes of administration.

Glenn started his career at Abbott Laboratories in 1989, after having completed his B.S in Pharmacy at Albany College of Pharmacy and his Ph.D. in Pharmaceutical Chemistry at the University of Connecticut. He then participated in a pharmaceutical professional development program for 2 ½ years, learning all aspects of pharmaceutical development. In 1995, Dr. Meyer moved to the CDMO space with Applied Analytical Inc. Labs in a managerial role and was Sr. Manager, Director and Sr. Director, ending with responsibility for all internal sponsored research. He served on the Management Teams for a Joint Venture with Tanabe-Seiyaku and a Collaborative License Agreement with Osmotica Pharmaceuticals.

At the end of 2001, Dr. Meyer left AAI to become the US founding employee as Chief Operating Officer at Osmotica Pharmaceuticals Inc and three years later as the Chief Scientific Officer working to development a pipeline of neuroscience candidates treating muscle spasticity, depression and Parkinson’s disease. During the 10 years at Osmotica, Dr. Meyer grew the company from inception to >$100 million/year in revenue and from the starting employee to over 250 employees.

Dr. Meyer left Osmotica in 2012 to start his own venture, assisting companies in developing the products best fitting the product profile required and serving the industry in making an optimal dosage form meeting the clinical endpoint, stability, bioavailability and desired product performance characteristics. Dr. Meyer has over 25 patents issued to date, numerous publications and continues to expand the boundaries of scientific knowledge through his product development efforts.

Let’s work together to change cancer’s trajectory

We look forward to talking to you. You may contact us for more information.

Let’s work together
to change cancer’s trajectory

We look forward to talking to you. You may contact us for more information.